Search
Now showing items 1-3 of 3
Developing drugs for developing countries.
(Health Aff (Millwood), 2006-03)
Infectious and parasitic diseases create enormous health burdens, but because most
of the people suffering from these diseases are poor, little is invested in developing
treatments. We propose that developers of treatments ...
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval
safety surveillance. There have been no systematic assessments of spending on postapproval
safety. We surveyed drug manufacturers regarding ...
Economic return of clinical trials performed under the pediatric exclusivity program.
(JAMA, 2007-02-07)
CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to
grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program
if industry sponsors complete FDA-requested pediatric ...